

# " Making the Intractable Tractable: Designing Multi-Functional, Epitope Specific Antibodies using Machine Learning "

Micah Pearlman, COO, Biojic Design

- **Investment Rational**

Biojic developed a proprietary computational-molecular antibody design platform (“Re-epitoping”) based on Machine Learning, which enables the discovery of Multibodies: antibodies that can bind and affect one or more targets while maintaining their fully human, natural IgG format, designed to engage multiple biological pathways to create a synergistic therapeutic benefit. The technology has been validated by more than a dozen partnerships with AstraZeneca and other top pharma.

- **Business Strategy**

Biojic Design uses its unique Machine Learning tools to develop a pipeline of Multibodies with near term inflection points, as a primary focus. Biojic is also actively collaborating with top pharma on selected projects. These collaborations typically entail upfront payments and longer-term milestone payments and royalties.

- **Core Technology**

### **Multibodies Create Opportunities for Novel, Differentiated Therapies**

Multibodies can disrupt combo therapies and bispecific markets - Binding multiple targets or different epitopes on the same target with high specificity while maintaining natural, human, IgG format. Making them simpler, faster, cheaper to manufacture and develop, with potentially higher efficacy due to better PK profile and lower toxicity compared with existing technologies. Additionally, Multibodies can be designed to bind where needed, agonize or antagonize challenging targets such as GPCR, Ion channels and cryptic epitopes, creating opportunities for first or best in class antibody-based therapeutics.

- **Product Profile / Pipeline**

Biojic’s proprietary pipeline is comprised of Multibodies focusing on difficult but validated targets and synergistic target combinations, where Biojic’s technology offers a competitive edge over other discovery technologies, increasing the probability of becoming the first or best in class. **Lead programs in Immuno-Oncology and Inflammation**, additional programs in oncology, immunology and CNS, First IND expected in 2021.

- **What’s next?**

Biojic is advancing its pipeline of Multibodies with lead assets entering preclinical development phases. Biojic is initiating a funding round to continue developing the pipeline and advance lead assets to phase 1.